News: GTG Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent..., page-2

Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO

MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s US patent application for its novel geneType COVID-19 Risk Test has been accepted:

• - New partnership agreement signed with IBX and 1health expands patient access in US.
• - Patent accepted by United States Patent and Trademark Office (“USPTO”) for the geneType COVID-19 Risk Test.
• - Cross validation of the geneType COVID-19 Risk Test completed in an independent cohort confirms test performance.
• - Spread of new and emerging variants including Omicron highlight the importance of understanding the risk of developing serious symptoms.

.
.
.
REF: https://finance.yahoo.com/news/genetic-technologies-announces-partnership-genetype-123000895.html

.